CR20200346A - Oligonucleótidos para modular la expresión de tmem106b - Google Patents
Oligonucleótidos para modular la expresión de tmem106bInfo
- Publication number
- CR20200346A CR20200346A CR20200346A CR20200346A CR20200346A CR 20200346 A CR20200346 A CR 20200346A CR 20200346 A CR20200346 A CR 20200346A CR 20200346 A CR20200346 A CR 20200346A CR 20200346 A CR20200346 A CR 20200346A
- Authority
- CR
- Costa Rica
- Prior art keywords
- oligonucleotides
- modulating
- tmem106b
- expression
- tmem106b expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
<p>La presente invenciòn se refiere a oligonuclèotidos que modulan o son complementarios de la expresión TMEM106B. Asimismo, la presente invención se refiere a conjugados de las composiciones de oligonuclèotidos y farmacéuticas y métodos para el tratamiento de trastornos neurológicos con el uso del oligonuclèotido.</p>
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18156142 | 2018-02-09 | ||
US201862669251P | 2018-05-09 | 2018-05-09 | |
PCT/EP2019/053116 WO2019154979A1 (en) | 2018-02-09 | 2019-02-08 | Oligonucleotides for modulating tmem106b expression |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20200346A true CR20200346A (es) | 2020-10-19 |
Family
ID=65433647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20200346A CR20200346A (es) | 2018-02-09 | 2019-02-08 | Oligonucleótidos para modular la expresión de tmem106b |
Country Status (17)
Country | Link |
---|---|
US (1) | US11485975B2 (es) |
EP (1) | EP3749766A1 (es) |
JP (1) | JP7281474B2 (es) |
KR (1) | KR20200108315A (es) |
CN (1) | CN111868245A (es) |
AU (1) | AU2019219194A1 (es) |
BR (1) | BR112020016170A2 (es) |
CA (1) | CA3088071A1 (es) |
CL (1) | CL2020002038A1 (es) |
CR (1) | CR20200346A (es) |
IL (1) | IL276357A (es) |
MA (1) | MA51795A (es) |
MX (1) | MX2020008290A (es) |
PE (1) | PE20211197A1 (es) |
RU (1) | RU2020125769A (es) |
SG (1) | SG11202007093YA (es) |
WO (1) | WO2019154979A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220275374A1 (en) * | 2019-11-14 | 2022-09-01 | The Board Of Regents Of The University Of Oklahoma | Oligonucleotide interference treatments of prostate cancer |
JP2023527684A (ja) * | 2020-05-11 | 2023-06-30 | ジェネンテック, インコーポレイテッド | 神経疾患を治療するための補体成分c1s阻害剤、並びにそれを使用する関連組成物、システム及び方法 |
WO2023141507A1 (en) * | 2022-01-20 | 2023-07-27 | Genentech, Inc. | Antisense oligonucleotides for modulating tmem106b expression |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
EP1557424A1 (en) | 1997-09-12 | 2005-07-27 | Exiqon A/S | Bi-cyclic nucleoside, nucleotide and oligonucleoide analogues |
BRPI0008131B8 (pt) | 1999-02-12 | 2021-05-25 | Daiichi Sankyo Co Ltd | composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno |
NZ514348A (en) | 1999-05-04 | 2004-05-28 | Exiqon As | L-ribo-LNA analogues |
US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
HU230458B1 (hu) | 2000-12-01 | 2016-07-28 | Europäisches Laboratorium für Molekularbiologie (EMBL) | Az RNS interferenciát közvetítő kis RNS molekulák |
EP1414840A4 (en) | 2001-03-27 | 2005-04-13 | Univ Delaware | GENOMIC APPLICATIONS FOR MODIFIED OLIGONUCLEOTIDES |
KR101021695B1 (ko) | 2001-07-12 | 2011-03-15 | 유니버시티 오브 매사추세츠 | 유전자 불활성화를 매개하는 소형 간섭 rna의 생체내 제조 |
JP2006507841A (ja) | 2002-11-14 | 2006-03-09 | ダーマコン, インコーポレイテッド | 機能的siRNAおよび超機能的siRNA |
DK1569661T3 (da) | 2002-11-18 | 2010-01-11 | Santaris Pharma As | Antisense design |
ES2576677T3 (es) | 2003-03-21 | 2016-07-08 | Roche Innovation Center Copenhagen A/S | Análogos de ARN interfirientes cortos |
CN101052717A (zh) | 2004-05-11 | 2007-10-10 | α基因株式会社 | 诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法 |
EP2397563A3 (en) | 2004-09-17 | 2012-07-18 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
DK1984381T3 (da) | 2006-01-27 | 2010-11-01 | Isis Pharmaceuticals Inc | 6-modificerede bicycliske nukleinsyreanaloger |
AU2007229161B2 (en) | 2006-03-23 | 2012-07-12 | Roche Innovation Center Copenhagen A/S | Small internally segmented interfering RNA |
US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
JP5665317B2 (ja) | 2006-10-18 | 2015-02-04 | アイシス ファーマシューティカルズ, インコーポレーテッド | アンチセンス化合物 |
US8278425B2 (en) | 2007-05-30 | 2012-10-02 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
DK2173760T4 (en) | 2007-06-08 | 2016-02-08 | Isis Pharmaceuticals Inc | Carbocyclic bicyclic nukleinsyreanaloge |
US8278283B2 (en) | 2007-07-05 | 2012-10-02 | Isis Pharmaceuticals, Inc. | 6-disubstituted or unsaturated bicyclic nucleic acid analogs |
US8546556B2 (en) | 2007-11-21 | 2013-10-01 | Isis Pharmaceuticals, Inc | Carbocyclic alpha-L-bicyclic nucleic acid analogs |
US8501805B2 (en) | 2008-09-24 | 2013-08-06 | Isis Pharmaceuticals, Inc. | Substituted alpha-L-bicyclic nucleosides |
CN102325534B (zh) | 2008-12-18 | 2016-02-17 | 戴瑟纳制药公司 | 延长的dicer酶底物和特异性抑制基因表达的方法 |
US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
SG10202109219SA (en) | 2009-05-02 | 2021-10-28 | Genzyme Corp | Gene therapy for neurodegenerative disorders |
EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
US8846637B2 (en) | 2010-06-08 | 2014-09-30 | Isis Pharmaceuticals, Inc. | Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
CN103068983A (zh) | 2010-06-11 | 2013-04-24 | 安提森斯制药有限公司 | 用于选择性寡核苷酸修饰的方法 |
AU2011325956B2 (en) * | 2010-11-12 | 2016-07-14 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
EP3467109A1 (en) | 2011-02-08 | 2019-04-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
CN103502273A (zh) | 2011-04-20 | 2014-01-08 | 罗氏格黎卡特股份公司 | 用于pH依赖性通过血脑屏障的方法和构建体 |
WO2013022966A1 (en) | 2011-08-11 | 2013-02-14 | Isis Pharmaceuticals, Inc. | Linkage modified gapped oligomeric compounds and uses thereof |
US9221864B2 (en) | 2012-04-09 | 2015-12-29 | Isis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
EP2850185A4 (en) * | 2012-05-16 | 2015-12-30 | Rana Therapeutics Inc | COMPOSITIONS AND METHODS FOR MODULATING UTRN EXPRESSION |
EA201492119A1 (ru) * | 2012-05-16 | 2015-05-29 | Рана Терапьютикс, Инк. | Композиции и способы для модулирования экспрессии apoa1 и abca1 |
US20150141320A1 (en) * | 2012-05-16 | 2015-05-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating gene expression |
KR102112892B1 (ko) * | 2012-11-15 | 2020-05-19 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | 올리고뉴클레오티드 콘쥬게이트 |
US10358643B2 (en) | 2014-01-30 | 2019-07-23 | Hoffmann-La Roche, Inc. | Poly oligomer compound with biocleavable conjugates |
US20150231151A1 (en) | 2014-02-19 | 2015-08-20 | University Of Houston System | Compositions and methods for the treatment of neurodegenerative diseases |
CN104450621B (zh) * | 2014-09-30 | 2018-10-19 | 首都医科大学附属北京口腔医院 | Wdr63基因在间充质干细胞骨向和牙向分化过程中的调控方法 |
US10799523B2 (en) * | 2015-02-04 | 2020-10-13 | F. Hoffmann-La Roche Ag | Tau antisense oligomers and uses thereof |
US20180023081A1 (en) * | 2015-02-04 | 2018-01-25 | Bristol-Myers Squibb Company | Lna oligonucleotides with alternating flanks |
-
2019
- 2019-02-08 MX MX2020008290A patent/MX2020008290A/es unknown
- 2019-02-08 RU RU2020125769A patent/RU2020125769A/ru not_active Application Discontinuation
- 2019-02-08 BR BR112020016170-5A patent/BR112020016170A2/pt not_active Application Discontinuation
- 2019-02-08 AU AU2019219194A patent/AU2019219194A1/en not_active Abandoned
- 2019-02-08 PE PE2020001186A patent/PE20211197A1/es unknown
- 2019-02-08 MA MA051795A patent/MA51795A/fr unknown
- 2019-02-08 SG SG11202007093YA patent/SG11202007093YA/en unknown
- 2019-02-08 CA CA3088071A patent/CA3088071A1/en not_active Abandoned
- 2019-02-08 CN CN201980020478.1A patent/CN111868245A/zh active Pending
- 2019-02-08 KR KR1020207022883A patent/KR20200108315A/ko not_active Application Discontinuation
- 2019-02-08 WO PCT/EP2019/053116 patent/WO2019154979A1/en unknown
- 2019-02-08 CR CR20200346A patent/CR20200346A/es unknown
- 2019-02-08 JP JP2020542377A patent/JP7281474B2/ja active Active
- 2019-02-08 EP EP19705306.9A patent/EP3749766A1/en active Pending
-
2020
- 2020-07-28 IL IL276357A patent/IL276357A/en unknown
- 2020-08-05 CL CL2020002038A patent/CL2020002038A1/es unknown
- 2020-08-06 US US16/987,030 patent/US11485975B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20210054383A1 (en) | 2021-02-25 |
JP2021514182A (ja) | 2021-06-10 |
IL276357A (en) | 2020-09-30 |
CL2020002038A1 (es) | 2020-10-23 |
BR112020016170A2 (pt) | 2020-12-15 |
MX2020008290A (es) | 2020-09-25 |
KR20200108315A (ko) | 2020-09-17 |
RU2020125769A (ru) | 2022-03-10 |
RU2020125769A3 (es) | 2022-03-10 |
PE20211197A1 (es) | 2021-07-01 |
AU2019219194A1 (en) | 2020-08-06 |
CN111868245A (zh) | 2020-10-30 |
WO2019154979A1 (en) | 2019-08-15 |
MA51795A (fr) | 2020-12-16 |
JP7281474B2 (ja) | 2023-05-25 |
CA3088071A1 (en) | 2019-08-15 |
SG11202007093YA (en) | 2020-08-28 |
EP3749766A1 (en) | 2020-12-16 |
US11485975B2 (en) | 2022-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020550523A1 (en) | Modulators of the integrated stress pathway | |
ZA202004100B (en) | Diaryl macrocycles as modulators of protein kinases | |
MX2023009561A (es) | Moduladores de profarmacos de la via de estres integrada. | |
MX2021013193A (es) | Cicloalquilos sustituidos como moduladores de la vía integrada del estrés. | |
EP3862362A3 (en) | Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression | |
NZ750174A (en) | Somatostatin modulators and uses thereof | |
NZ757081A (en) | Somatostatin modulators and uses thereof | |
PH12019502363A1 (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
MX2016002075A (es) | Inhibidores de indolamina 2,3-dioxigenasa (ido). | |
MX2015012056A (es) | Inhibidores de indolamina-2,3-dioxigenasa (ido). | |
MX2016000295A (es) | Inhibidores de indoleamina 2,3-dioxigenasa (ido). | |
CR20200346A (es) | Oligonucleótidos para modular la expresión de tmem106b | |
MX2020007586A (es) | Proceso de fabricacion de moduladores de somatostatina. | |
MX2022005775A (es) | Compuestos terapeuticos y metodos de uso. | |
GEP20217318B (en) | Pyrazole magl inhibitors | |
MX2020000523A (es) | Compuestos de isocromano y usos de los mismos. | |
MX2022006862A (es) | Inhibidores duales de magl y faah. | |
MX2022000712A (es) | Moduladores de nlrp3. | |
MX2022011310A (es) | Azabiciclo y derivados de diazepina para tratar trastornos oculares. | |
MX2021008941A (es) | Moduladores gpr35. | |
MX2019008554A (es) | Moduladores de los receptores a3 de adenosina. | |
JOP20210332A1 (ar) | عقاقير أولية لمعدلات المستقبل nmda | |
MX2021015742A (es) | Moduladores del receptor de nmda. | |
TW201612183A (en) | Diaryl macrocycles as modulators of protein kinases | |
EA202191927A1 (ru) | Модуляторы gpr35 |